Drugs with this side effect
- 2-hydroxysuccinaldehyde: 0% - 7%
- 5-ASA: postmarketing, 3%
- 5-aminolevulinic acid
- 5-aza-2'-deoxycytidine: 16.2%
- CGP 19835A: very common, 89%
- Cancidas: 0% - 75.3%
- Carfilzomib: 0% - 16%
- EDTA
- Enfuvirtide
- FAMP: 11% - 19%
- Fe(III: postmarketing
- Gd-DTPA
- Gd-EOB-DTPA
- Ge-132: 43% - 59%
- Glat copolymer
- Goserelin: 1-10%
- K779: 16% - 54%
- L-Dmp: infrequent
- LY146032: uncommon
- Leuprorelin
- Lisinopril
- Lovaza
- Lutalyse
- Meropenem anhydrous
- Metrodin
- Optison
- PCI-32765
- PGE2
- Refludan
- Romidepsin: 0% - 17%
- S-benzoylmercaptoacetyltriglycine
- TlCl
- UDCA
- VACV: 1% - 1.6%
- Vancocine: postmarketing
- abacavir: 12%
- acamprosate: frequent
- actinomycin D
- alfentanil: 1.8%
- allopurinol
- almotriptan: infrequent
- amifostine
- amphetamine
- amphotericin B: 6% - 89.7%
- anagrelide: 1-5%
- anthracycline
- aprepitant
- aripiprazole
- arsenic trioxide
- atomoxetine: 3%
- azithromycin
- baclofen: common, 0% - 1.33%
- belinostat: 1% - 16%
- bendamustine: 0% - 5.88%
- benzathine penicillin
- bexarotene: 9.52% - 13.2%
- bicalutamide
- bleomycin hydrochloride
- boceprevir: very common, 29% - 30%
- bortezomib
- bromcresol green: 0% - 9%
- bupivacaine
- buprenorphine: 4.84% - 7.77%
- bupropion: postmarketing, infrequent, 1.2%
- buspirone: infrequent
- busulfan: 46%
- butorphanol
- cabazitaxel
- cabozantinib
- capecitabine
- carbamazepine
- carbinoxamine
- carboplatin
- carboprost
- cefaclor
- cefepime
- cefpodoxime
- ceftobiprole
- ceftriaxone
- cefuroxime
- cefuroxime axetil
- cerivastatin
- chlorpheniramine
- cidofovir: postmarketing, 21.7%
- cilostazol
- ciprofloxacin: postmarketing
- citalopram: infrequent
- citric acid
- cladribine: very common, 2% - 9%
- clarithromycin
- clemastine
- clofarabine: common
- clomipramine: 2%
- clozapine
- copolymer 1
- cyclizine
- cyclophosphamide: postmarketing
- cyproheptadine
- cyproterone acetate
- dabrafenib: very common, 0% - 58%
- dalteparin
- danazol
- dantrolene
- darunavir
- dasatinib: common, 0% - 11%
- deferiprone: postmarketing
- degarelix: 0% - 5%
- delavirdine
- delta 9-THC: postmarketing
- deprenyl: infrequent
- desmopressin: 0% - 2%
- desvenlafaxine: 1% - 4%
- dexmedetomidine: 2%
- diatrizoate
- diazepam
- diclofenac: 0% - 2%
- didanosine: postmarketing
- dimercaptosuccinic acid
- diphenhydramine
- docetaxel: 0%
- dolasetron: 1.28% - 2.74%
- donepezil: infrequent
- doxepin: rare
- doxorubicin: postmarketing, common, 0.3% - 6.4%
- droperidol
- duloxetine: postmarketing, common, frequent
- eletriptan: frequent
- eltrombopag
- eribulin
- ertapenem
- eslicarbazepine acetate
- estazolam: infrequent
- ethacrynic acid
- etodolac
- etoposide: 24%
- etoposide phosphate
- everolimus: 4%
- exenatide
- fentanyl
- fludarabine: 11% - 19%
- flumazenil
- flunisolide
- fluorescein: postmarketing
- fluoxetine: infrequent, common, frequent
- flurbiprofen
- fluvastatin: postmarketing
- fluvoxamine: rare, infrequent, 2%
- fosinopril: uncommon
- fosphenytoin: frequent
- gabapentin: infrequent
- gadobenate dimeglumine
- gadolinium: 0.1%
- gadopentetate: postmarketing
- gadoversetamide
- ganciclovir
- gatifloxacin
- gemcitabine
- gemeprost
- gliclazide
- glipizide
- glucose solution
- glutamine: 0% - 11.1%
- glycine
- granisetron
- heparin: postmarketing
- hepatitis B vaccines
- hetastarch: postmarketing
- histamine
- hydralazine
- hydromorphone
- hydroxocobalamin
- hydroxybutyrate
- hydroxyurea
- ibandronate
- ibuprofen
- icodextrin: postmarketing
- idarubicin
- ifosfamide: postmarketing
- imatinib: common, 3% - 11%
- imiquimod
- indinavir
- iodipamide
- iopamidol
- iopromide: postmarketing
- iotrolan
- ioversol
- ioxaglate
- ioxilan
- irbesartan
- irinotecan: 0% - 14%
- iron sucrose
- isocarboxazid
- itraconazole
- ivermectin
- ixabepilone
- ketoconazole
- ketoprofen
- ketorolac tromethamine
- lamivudine: 12%
- lamotrigine: infrequent
- lansoprazole
- leflunomide
- lenalidomide
- leuprorelin acetate
- linezolid
- lomefloxacin
- lomitapide
- lorazepam: infrequent
- lorcaserin
- lovastatin: postmarketing
- mannitol
- mebrofenin
- medroxyprogesterone: postmarketing
- medroxyprogesterone acetate: postmarketing
- mefloquine: postmarketing
- mepivacaine
- meprobamate
- meropenem
- metaproterenol: 0.2% - 1%
- metformin
- methadone
- methotrexate
- methylene diphosphonate
- methylphenidate
- metolazone
- miconazole
- midazolam
- midodrine: 0% - 4.9%
- mifepristone
- miglustat: common, 0% - 8%
- milnacipran: 1% - 2%
- mipomersen: 6%
- mirtazapine: infrequent
- misoprostol: postmarketing
- mitoxantrone
- modafinil
- morphine
- moxifloxacin
- mycophenolate mofetil: 10.1% - 11.4%
- mycophenolic acid
- nabilone
- nabumetone: postmarketing, 0.2%
- nalmefene: 1%
- naltrexone
- naproxen: postmarketing
- naratriptan: infrequent
- nefazodone
- niacin
- nifedipine
- nilotinib: uncommon
- nisoldipine
- nitazoxanide
- nitrofurantoin
- norfloxacin
- ofatumumab: 0% - 10%
- ofloxacin
- olanzapine: rare, infrequent
- oxaliplatin
- oxycodone
- oxymetholone
- paclitaxel: rare, very common
- paliperidone
- palonosetron
- pantoprazole
- paricalcitol: 4.8%
- paroxetine: rare, infrequent, uncommon, frequent
- pazopanib
- penicillin
- pentamidine
- pentazocine
- pentostatin: 11% - 34%
- pergolide: infrequent, 1.1%
- perindopril
- perindopril erbumine
- phenytoin: frequent
- pilocarpine: 3% - 15%
- piroxicam
- pixantrone
- pomalidomide: 9.35% - 10.7%
- ponatinib: 0% - 13%
- posaconazole
- pramipexole
- pravastatin: postmarketing
- pregabalin: rare, infrequent
- procainamide
- procaine penicillin
- procarbazine
- propofol
- prostacyclin: 11% - 25%
- quetiapine: infrequent, 1%
- quinidine
- rabeprazole
- raltegravir
- rapamycin: 2%
- rasagiline: infrequent
- reboxetine: 2.43%
- remifentanil: 1.26% - 3.17%
- ribavirin: 21% - 39%
- rifampicin
- riluzole: infrequent
- risperidone
- ritonavir
- rizatriptan
- rofecoxib
- ropivacaine: 1.2% - 6.2%
- salbutamol
- salmon calcitonin acetate: uncommon
- samarium: 8.54%
- sevoflurane
- sibutramine
- sildenafil
- simvastatin: postmarketing
- sodium ferric gluconate
- sodium iothalamate
- sofosbuvir: very common, 1% - 18%
- sparfloxacin
- spectinomycin
- stavudine: postmarketing
- strontium
- sufentanil
- sugammadex
- sulfadiazine
- sulfamethoxazole
- sulindac
- sumatriptan: infrequent
- sunitinib
- tacrolimus
- tamsulosin: 0.7%
- tapentadol: 1%
- technetium-99m
- telavancin: common
- temsirolimus
- teniposide
- terconazole: postmarketing, 0.4%
- testosterone
- testosterone undecanoate
- tetracaine
- thalidomide: 0% - 11.4%
- thiabendazole
- thiotepa
- tiagabine: frequent
- tigecycline
- tiopronin
- tirofiban
- tolcapone: infrequent
- topotecan
- tramadol
- trametinib: 0% - 58%
- trans 4-cyclohexyl-L-proline
- tranylcypromine
- trazodone: postmarketing
- trovafloxacin
- valdecoxib
- valproate
- varenicline: infrequent
- venlafaxine: postmarketing, common, frequent, 2.2% - 6.8%
- vildagliptin: common
- vinflunine
- voriconazole: common, 0% - 19.5%
- vorinostat
- warfarin
- zalcitabine
- zaleplon: infrequent
- zanamivir: 5% - 9%
- zidovudine: rare
- zidovudine/lamivudine
- ziprasidone: frequent
- zoledronic acid: postmarketing, 1.5% - 18.2%
- zolmitriptan: infrequent
- zopiclone
|
Drugs with this indication
|
